Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

849.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
30 31 Next >
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough." 
Via Benzinga
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range 
Via Spotlight Growth
CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron
Via Benzinga
Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
CytomX Therapeutics (CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (REGN). 
Via InvestorPlace
Regeneron Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Regeneron Pharmaceuticals Tops Quarterly Expectations Despite Covid Shortfall
Excluding the year-earlier impact of the Covid drug, third-quarter sales grew 11%. 
Via Investor's Business Daily
Analyst Ratings for Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Daily Stock Analysis: Sanofi - November 2022 Snapshot
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company's decided in late 2019 to pull back from the cardio-metabolic... 
Via Talk Markets
2 Top Biotech Stocks to Buy in November
Both of these companies have potential catalysts on the way. 
Via The Motley Fool
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
$100 Invested In This Stock 15 Years Ago Would Be Worth $4,000 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.17% on an annualized basis producing an average annual return of 27.88%. Currently, Regeneron... 
Via Benzinga
7 Cash-Rich Stocks to Buy for Peace of Mind
It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven. 
Via InvestorPlace
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
A mixed jobs report and heavy earnings swung stocks. 
Via Investor's Business Daily
Regeneron Pharmaceuticals: Q3 Earnings Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange... 
Via Benzinga
Here's How Much $1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.24% on an annualized basis producing an average annual return of 27.82%. Currently, Regeneron... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’
If you see a blue wave coming get out of the oilpatch, crypto, and pharmaceuticals that are subject to price regulation. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
Upgrades 
Via Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These two durable companies can navigate the market downturn and beyond. 
Via The Motley Fool
Steady As She Goes With Healthcare Stocks
Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports. 
Via Talk Markets
If You Invested $100 In This Stock 20 Years Ago, You Would Have $5,000 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.25% on an annualized basis producing an average annual return of 21.62%. Currently, Regeneron... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022
Upgrades 
Via Benzinga
13 Analysts Have This to Say About Regeneron Pharmaceuticals
Over the past 3 months, 13 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Why Cash-Rich Companies And #ETFs Are Beating The Market?
Investors believe that “cash is king” in the current environment of surging inflation, rising rates, and a potential economic downturn. ETFs that hold cash-rich companies have seen a lot of interest... 
Via Talk Markets
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.